RenovoRx Inc (NASDAQ:RNXT) — Market Cap & Net Worth
Market Cap & Net Worth: RenovoRx Inc (RNXT)
RenovoRx Inc (NASDAQ:RNXT) has a market capitalization of $38.29 Million ($38.29 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22934 globally and #4954 in its home market, demonstrating a 3.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RenovoRx Inc's stock price $0.89 by its total outstanding shares 45052706 (45.05 Million). Review total liabilities of RenovoRx Inc to assess the company's total debt and financial obligations.
RenovoRx Inc Market Cap History: 2021 to 2026
RenovoRx Inc's market capitalization history from 2021 to 2026. Data shows change from $218.06 Million to $40.13 Million (-35.35% CAGR).
Index Memberships
RenovoRx Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #656 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2184 of 3165 |
Weight: RenovoRx Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
RenovoRx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RenovoRx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.70x
RenovoRx Inc's market cap is 33.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $58.12 Million | $43.00K | -$8.81 Million | 1351.58x | N/A |
| 2025 | $37.85 Million | $1.12 Million | -$11.17 Million | 33.70x | N/A |
Competitor Companies of RNXT by Market Capitalization
Companies near RenovoRx Inc in the global market cap rankings as of June 18, 2026.
Key companies related to RenovoRx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
RenovoRx Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, RenovoRx Inc's market cap moved from $218.06 Million to $ 40.13 Million, with a yearly change of -35.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $40.13 Million | +6.02% |
| 2025 | $37.85 Million | -34.88% |
| 2024 | $58.12 Million | -43.67% |
| 2023 | $103.17 Million | -2.55% |
| 2022 | $105.87 Million | -51.45% |
| 2021 | $218.06 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of RenovoRx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.29 Million USD |
| MoneyControl | $38.29 Million USD |
| MarketWatch | $38.29 Million USD |
| marketcap.company | $38.29 Million USD |
| Reuters | $38.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more